Advertisement
News
Advertisement

pSivida, Alimera Sciences soar as Iluvien skips ahead to FDA review

Thu, 12/19/2013 - 1:58pm
Mass Device

pSivida's shares spike 35% on news that the company's Iluvien eye drug/device combination will skip ahead to final FDA review, bypassing the advisory panel process.

pSivida soars as copmany skips FDA avisory panel on review path for Iluvien

Massachusetts-based pSivida (NSDQ:PSDV) is making a comeback, with shares soaring on news that the company and its licensee Alimera Sciences (NSDQ:ALIM)  will get to skip past the advisory panel committee meeting and head straight to final FDA review for the Iluvien drug-device combination.

The regulatory win marks a major turnaround for the companies and the Iluvien product, which as been thrice denied by FDA regulators, most recently in October.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading